. 1 The ability of Tregs to mediate immunosuppressive effects has previously been shown to depend on increases in the intracellular concentration of cAMP [2] [3] [4] ( Fig. 1A) . Intracellular cAMP levels reflect the rate of cAMP synthesis by adenylate cyclases (ACs), degradation by phosphodiesterases (PDEs), or excretion (Fig. 1A) . In Tregs, the activity of AC9 and the expression of PDE3B are regulated by the lineage-defining transcription factor forkehead box P3 (FOXP3). 4, 5 However, the IFNα-mediated inactivation of Tregs did not affect FOXP3 expression levels. In line with this notion, IFNα also failed to alter the methylation state of the FOXP3 locus, which is required for stable FOXP3 expression and suppressive functions. 1 Thus, IFNα disturbs the immunosuppressive activity of human Tregs without affecting their imprinted lineage phenotype.
A prominent and well-known activity of IFNα consists in the activation of the MEK/ERK signaling pathway, 5 and active mitogen-activated protein kinase 1 (MAPK1, also known as ERK2) is able to stimulate the enzymatic activity of 2 short PDE4 isoforms that are predominantly expressed in T cells, namely PDE4B and PDE4D (Fig. 1B) . 6 Consistent with the ability of IFNα to activate PDE4 via ERKs, the global inhibition of ERKs or PDEs, as well as the specific inhibition of PDE4, restored the immunosuppressive activity of Tregs exposed to IFNα (Fig. 1C) . In addition to regulating the intracellular pool of cAMP, IFNα decreased the T-cell receptor (TCR)-induced activation of ζ chain (TCR) associated protein kinase 70kDa (ZAP70) in Tregs, supposedly by recruiting ZAP70 molecules to the interferon-α receptor (IFNAR), hence limiting their availability in TCRmediated signal transduction. (Fig. 1C) . 1 Interestingly, using a xenogeneic graft vs. host disease (GvHD) model applicable for the functional analysis of human Tregs, we found that the preincubation of Tregs with IFNα abrogated their ability to protect from disease onset. The administration of IFNα has been previously observed to reduce the number of Tregs in melanoma and renal cell carcinoma patients. 9 Conversely, declining IFNα levels and impaired IFNα signaling have been correlated with an elevation in the number of Tregs as well as with an increased risk of tumor progression. 10 The repression of human Treg functions by IFNα may significantly contribute to its antineoplastic effects and provides a rationale for considering IFNα as a potent Treg-inactivating agent in the context of anticancer vaccination. In line with this assumption, improved immune responses have been reported in renal, pancreatic, and colorectal cancer patients upon the co-administration of IFNα with peptide vaccines. However, whether the prolonged administration of IFNα to cancer patients can recapitulate and/ or stimulate all or only specific subsets of tumor-specific T cells remains to be investigated. Moreover, in accordance with its role in autoimmune diseases, the continuous administration of therapeutic doses of IFNα also increases the risk of developing autoimmune symptoms, as frequently observed in cancer patients receiving IFNα-based immunotherapy.
Altogether, our findings reveal an hitherto unrecognized function of IFNα that provides a logical explanation for its robust immunostimulatory activity in cancer patients, including frequently observed autoimmune symptoms upon continuous therapeutic application. 1066/B8 to C.B. and T.B., by the German Cancer Aid (K.S.) and by intramural grants to KS, C.B. and N.B. (MAIFOR, NMFZ).
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No potential conflicts of interest were disclosed. Figure 1 (See previous page) . Interferon α signaling interferes with the TCr-dependent production of caMP in regulatory T cells. (A) T-cell receptor (TCr) signaling causes an increase in the intracellular pool of cyclic adenosine monophosphate (caMP) of regulatory T cells, as well as the transmission of caMP via gap junctions to responder cells. In natural killer (NK) cells or effector T lymphocytes targeted by Tregs, caMP limits effector functions by a hitherto undefined mechanism. (B) The binding of interferon α (IFNα) to its receptor activates the MeK-erK signaling pathway, probably via the JaK-sTaT axis. activated erK in turn stimulates the enzymatic activity of short phosphodiesterase 4 isoforms predominantly expressed in T cells, namely, PDe4B and PDe4D, resulting in a decrease in intracellular (and hence transmittable) caMP. (C) Blocking the MeK-erK signaling pathway or the enzymatic activity of PDe4 with specific inhibitors counteracts the ability of IFNα to repress caMP production and hence restores the immunosuppressive functions of Tregs.
